We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Phosphagenics has announced the interim results from its Phase I transdermal insulin trial, which demonstrate that insulin was successfully delivered through the skin using transdermal carrier technology.
Diamyd Medical has announced that its lead drug candidate, Diamyd, has demonstrated statistically significant efficacy in preserving insulin production in a Phase II clinical trial in 70 children and adolescents with Type 1 diabetes.
Genentech and Biogen Idec announced that a Phase II study of Rituxan (Rituximab) for relapsing-remitting multiple sclerosis (MS) met its primary endpoint.
Theratechnologies has received special protocol assessment (SPA) from the FDA for the design of its second Phase III trial evaluating TH9507 for the treatment of HIV-associated lipodystrophy.
Corcept Therapeutics announced that the results of the first of its three Phase III trials evaluating Corlux for treating psychotic major depression were negative.
The FDA has approved the use of UCB's Keppra (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 and older with juvenile myoclonic epilepsy.
Questcor Pharmaceuticals announced that the FDA has accepted for review its supplemental new drug application seeking approval for H.P. Acthar gel (repository corticotropin injection) for the treatment of infantile spasms.
Dendreon has submitted the clinical and non-clinical sections of the rolling submission of a biologics license application (BLA) to the FDA for Provenge (sipuleucel-T) for the treatment of asymptomatic patients with metastatic, androgen-independent prostate cancer.